Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE)
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs AR 101 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Registrational
- Acronyms RAMSES OLE
- Sponsors Aimmune Therapeutics
- 06 Nov 2019 Status changed from active, no longer recruiting to completed.
- 19 Aug 2019 Planned End Date changed from 1 Jul 2019 to 24 Oct 2019.
- 18 Apr 2019 Planned End Date changed from 1 Apr 2019 to 1 Jul 2019.